AI assistant
Beta Bionics, Inc. — Director's Dealing 2025
Dec 2, 2025
32351_dirs_2025-12-02_5cda9cd9-6846-4619-90c1-7a3bcb54d81b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Beta Bionics, Inc. (BBNX)
CIK: 0001674632
Period of Report: 2025-12-01
Reporting Person: Lezack Adam (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-12-01 | Common Stock | S | 906 | $29.3463 | Disposed | 8935 | Direct |
| 2025-12-01 | Common Stock | S | 500 | $29.91 | Disposed | 8435 | Direct |
Footnotes
F1: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on July 31, 2025.
F2: The weighted average sale price for the transaction reported was $29.3463 and the range of prices were between $28.75 and $29.63. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F3: The weighted average sale price for the transaction reported was $29.91 and the range of prices were between $29.80 and $30.16. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.